MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside…
MENLO PARK, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the…
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025 Q3…
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025 Q3…
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics…
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia MENLO PARK, Calif., Nov. 04,…
MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results…
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ:…
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE)…
Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies of healthy aging to date MENLO PARK, Calif., Oct. 08,…
Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing MENLO PARK, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) — PacBio…
Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading…
New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer MENLO PARK, Calif., Sept….
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results: Q2 2025 Q2…
MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the…
Clear filters
If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.